



(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 9/10 (2006.01)
A61P 7/02 (2006.01) C07D 401/14 (2006.01)

(21) International Application Number:

PCT/US2024/025410

(22) International Filing Date:

19 April 2024 (19.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/497,088	19 April 2023 (19.04.2023)	US
63/497,101	19 April 2023 (19.04.2023)	US
63/497,111	19 April 2023 (19.04.2023)	US
63/578,508	24 August 2023 (24.08.2023)	US
63/582,313	13 September 2023 (13.09.2023)	US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **LI, Danshi**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **NESSER, Christopher**; 555 US Highway 22 W, Bridgewater, New Jersey 08807 (US). **PLOTNIKOV, Alexei**; 555 US Highway 22 W, Bridgewater, New Jersey 08543 (US). **BARNATHAN, Elliot**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **STRONY, John**; 920 US Highway 202 S, Raritan, New Jersey 08869 (US). **PETERS, Gary**; 920 US Highway 202 S, Raritan, New Jersey 08869 (US). **CHINTALA, Madhu**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **LUETTGEN, Joseph**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **MOHAN, Puneet**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **HORROW, Jay**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **LODISE, Stephanie A.** et al.; Bakerhostetler, 1735 Market Street, Suite 3300, Philadelphia, Pennsylvania 19103-7501 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: USE OF MILVEXIAN IN THE TREATMENT AND PREVENTION OF THROMBOTIC CONDITIONS IN PATIENTS WITH CARDIOVASCULAR OR CEREBROVASCULAR DISEASE




FIG. 1

(57) Abstract: A Factor XIa inhibitor having therapeutic properties useful in methods for preventing a thrombotic condition in human patients with a cardiovascular or cerebrovascular disease.

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))